Cascade Investment, L.L.C. and William H. Gates III filed a Form 4 with the SEC on September 10, 2026, reporting six open-market purchases of Republic Services, Inc. common stock executed on September 8 and September 9, 2026.
Priced at a fraction of a cent, Odyssey Health, Inc. (OTC:ODYY) is the kind of speculative micro-cap that can post an eye-catching percentage gain on almost no dollar movement.
A Form 4 filed with the SEC on September 10, 2026 reports that John T. Hall, Chief Executive Officer and Director of Intapp, Inc. (NASDAQ:INTA), exercised stock options and sold common stock on September 8, 2026 pursuant to a pre-established trading plan.
Scott A. Hudson, EVP and President of Vistra Retail at Vistra Corp. (NYSE:VST), filed a Form 4 on September 10, 2026, disclosing the sale of 44,444 shares of common stock on September 8, 2026, pursuant to a Rule 10b5-1 trading plan.
Nathaniel Robinson, EVP and Chief Investment & Strategy Officer at Cushman & Wakefield Ltd. (NYSE:CWK), filed a Form 4 on September 10, 2026, disclosing the sale of 12,500 common shares on September 8, 2026.
Kristopher E. Moldovan, Executive Vice President and Chief Financial Officer of Vistra Corp. (NYSE:VST), filed a Form 4 on September 10, 2026, disclosing the sale of 20,000 shares of Vistra Corp. common stock on September 8, 2026, held indirectly through a family trust.
Director Kathy L. Hibbs of SOPHiA GENETICS SA filed a Form 4 on September 10, 2026, reporting the sale of 6,250 ordinary shares on September 8, 2026, pursuant to a Rule 10b5-1(c) trading plan.
Ryan Cohlhepp, President, COO and Interim CEO of Bicara Therapeutics Inc., filed a Form 4 on September 10, 2026, reporting stock option exercises and common stock sales that took place on September 8, 2026, pursuant to a Rule 10b5-1 trading plan.
Andrew Senn, President of Growth & Innovation at Integer Holdings Corp, filed a Form 4 with the SEC on September 10, 2026, reporting the sale of 9,408 shares of common stock on September 8, 2026.
David Ball, Executive Vice President and Chief Business Development Officer of Perrigo Company plc, filed a Form 4 on September 10, 2026, disclosing transactions in ordinary shares stemming from the vesting of Restricted Stock Units on September 9, 2026.